Chemopreventive activity of a macrofungus Phellinus rimosus against N-nitrosodiethylamine induced hepatocellular carcinoma in rat

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 4, 2006, Pages 309-321

  Ajith, Thekkuttuparambil Ananthanarayanan ^a   Janardhanan, Kainoor Krishnankutty ^b  

^a AMALA INSTITUTE OF MEDICAL SCIENCES   (India)

^b AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Anti inflammatory; Antimutagenecity; Antioxidant; Chemoprevention Hepatocellular carcinoma; Phellinus rimosus

Indexed keywords

4 NITRO 1,2 PHENYLENEDIAMINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; ANTIMUTAGENIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BENZO[A]PYRENE; CARRAGEENAN; DEXTRAN; DIETHYLNITROSAMINE; FIBRINOGEN; FORMALDEHYDE; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HYDROXYL RADICAL; MALONALDEHYDE; NITRIC OXIDE; PHELLINUS RIMOSUS EXTRACT; PHENOBARBITAL; SCAVENGER; SUPEROXIDE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMES TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AQUEOUS SOLUTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL STRAIN; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; FIBRINOGEN BLOOD LEVEL; FUNGUS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; LIPID PEROXIDATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; PAW EDEMA; PHELLINUS RIMOSUS; PRIORITY JOURNAL; RAT; SALMONELLA TYPHIMURIUM; SCAVENGING SYSTEM;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; FUNGI; HYDROXYL RADICAL; INHIBITORY CONCENTRATION 50; LIPID PEROXIDATION; LIVER; LIVER NEOPLASMS; MALE; MUTAGENS; NITRIC OXIDE; RATS;

EID: 33749356589     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Sheu JC, Huang GT, Lee PO, Chung HC, Lai MY, Wang JT. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res 52: 6098-6100, 1992.
2. Preussmann R, Stewart BW. N-nitrosocarcinogens. In: Searle CE, ed. Chemical Carcinogens. Washington: American Chemical Society 302-304, 1984.
3. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191-1308, 1981.
4. Waynder EL, Gorbi GB. Contributuion of the environment to cancer incidence: an epidemiological exercise. J Natl Cancer Inst 58: 825-832, 1977.
5. Block G. The data support a role for antioxidants in reducing cancer risk. Nutr Rev 50: 207-213, 1992.
6. Weitzman SA, Weitberg AB, Clark EP, Stossel TP. Phagocytes as carcinogens: malignant trasformation produced by human neutrophils. Science 227: 1231-1233, 1985.
7. Boone CW, Kelloff G J, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res 50: 2-9, 1990.
8. Jong SC, Birmingham JM. Edible mushrooms in Biotechnology. Proc Asian Mycol Symp, Seoul, Korea, 18-35, 1992.
9. Song YS, Kim SH, Sa JH, Jin C, Lim CJ, Park EH. Antiangiogenic, antioxidant and xanthine oxidase inhibition activities of the mushroom Phellinus linteus. J Ethnopharmacol 88: 113-116, 2003.
10. Ajith TA, Janardhanan KK. Antioxidant and anti-inflammatory activities of methanol extract of Phellinus rimosus. Ind J Exp Biol 39: 1166-1169, 2001.
11. Ajith TA, Jose N, Janardhanan KK. Amelioration of cisplatin induced nephrotoxicity in mice by ethyl acetate extract of a polypore fungus, Phellinus rimosus. J Exp Clin Cancer Res 21: 487-491, 2002.
12. Ajith TA, Janardhanan KK. Antioxidant and antihepatotoxic activities of Phellinus rimosus (Berk) Pilat. J Ethnopharmacol 81: 387-391, 2002.
13. Mc Cord J M, Fridovich I. Superoxide dismutase, an enzymatic function for erythrocuprein. J Biol Chem 244: 6049-6055, 1969.
14. Bishayee S, Balasubramanian AS. Lipid peroxidation in rat brain. J Neuro Chem 18: 909-913, 1971.
15. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Annal Biochem 95: 351-358, 1979.
16. Sreejayan M, Rao MNA. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 58: 237-240, 1997.
17. Maron DM, Ames BN. Revised methods for the salmonella mutagenecity test. Mutat Res 113: 173-215, 1983.
18. Ames BN, Purston WE, Yamasaki E, Lee FD. Carcinogens are mutagens: a simple test system combining liver homogenate for activation of bacteria for detection. Proc Natl Acad Sci 70: 3555-3559, 1973.
19. Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 227: 321-332, 1996.
20. Jose JK, Joy KL, Kuttan R. Effect of Emblica officinalis, Phyllanthus amarus and Picrorrhiza kurroa on N-nitrosodiethylamene induced hepatocellular carcinogenesis. Cancer Lett 135: 1-6, 1999.
21. Szasz G. Reaction-rate method for gamma glutamyl transferase activity in serum. Clinical Chem 22: 2051-2055, 1976.
22. Reitman S, Frankel AS. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 28: 56-63, 1957.
23. Varley H. The plasma proteins. In: Varley H, ed. Practical Clinical Biochemistry. Delhi: CBS Publishers and Distributors 230-274, 1980.
24. Varley H, Gowenlock AH, Bell M. The plasma proteins. In: Varley H, Gowenlock AH, Bell M, eds. Practical Clinical Biochemistry. London: Heinemann Professional Publishing Ltd. 535-595, 1980.
25. Kind PRN, King E J. Estimation of plasma phosphatase by determination of hydrolyzed phenol with antipyrene. J Clin Pathol 7: 322-326, 1954.
26. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 90: 37-43, 1987.
27. Moron MA, Depierre JW, Mannervik B. Levels of glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochemica et Biophysica Acta 582: 67-78, 1979.
28. Habig WH, Pabst MJ, Jakoby WR. Glutathione S-transferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 249: 7130-7139, 1974.
29. Hafemann DG, Sunde RA, Houestra WG. Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rat. J Nutr 104: 580-584, 1974.
30. Lowry HD, Rosenberg NJ, Farr AL, Randa RJ. Protein measurement with Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
31. Satosh K, Hatayama I, Tsuchida S, Sato K. Biochemical characteristics of a preneoplastic marker enzyme glutathione s-transferase P-form (7-7). Arch Biochem Biophys 285: 312-316, 1991.
32. Amemiya N, Yatomi Y, Endo T, Mizoe A, Yoda-Endo M, Yuminamochi T. A case of hepatocellular carcinoma with marked hyperfibrinogenemia. Acta Haematol 97: 236-238, 1997.
33. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320, 1994.
34. Boitier E, Merad-Boudia M, Guguen-Guillouzo C, Defer N, Ceballos-Picot I. Impairment of the mitochondrial respiratory chain activity in diethylnitrosamine induced rat hepatomas: possible involvement of free radical. Cancer Res 55: 3028-3035, 1995.
35. Park JW, Floid RA. Lipid peroxidation products mediate the formation of 8-hydroxydeoxyguanoine in DNA. Free Radical Biol Med 12: 245-250, 1992.
36. Ramal C, Alekperov UK, Ames BN, Kada T, Watttenberg LW. Inhibitors of mutagenesis and their relevance to carcinogenesis. Mutat Res 168: 47-65, 1986.
37. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR (1992). DNA damage and mutation in human cells exposed to nitric oxide in vivo. Proc Natl Acad Sci, USA 89: 3030-3034, 1992.
38. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Rad Biol Med 18: 775-794, 1995.
39. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci, USA 87: 1620-1623, 1990.
40. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human trials: A review. Cancer Res 50: 2-9, 1990.
41. Smith WA, Gupta RC. Use of a microsome-mediated test system to assess efficacy and mechanisms of cancer chemopreventive agents. Carcinogenesis 17: 1285-1290, 1996.
42. Lesko SA, Caspary W, Lorentzen R, Pop T. Enzymic formation of 6-oxobenzo(a)pyrene radical in rat liver homogenate from carcinogenic benzo(a)pyrene. Biochemistry 14: 3978-3982, 1975.
43. Grisham MB, Ware K, Gilliland HE, Jr Gilleland LB, Abell CL, Yamada T. Neutrophil-mediated nitrosamine formation: role of nitric oxide in rats. Gastroeneterology 103: 1260-1266, 1992.
44. Kunz KS, Klein T, Schwarz R. Effect of lindane and Phenobarbital on cyclooxygense-2 expression and prostanoid synthesis by Kuffer cells. Carcinogenesis 20: 1411-1416, 1999.
45. Santos ARS, De Campos ROP, Miguel OG, Filho VC, Siani AC, Yunes RA. Antinociceptive properties of extracts of new species of plants of the genes Phyllanthus (Euphorbiaceae). J Ethnopharmacol 72: 229-238, 2000.
46. Fukushima M. The over dose of drugs in Japan. Nature 342: 850-851, 1989.
47. Jong SC, Birmingham JM, Pai SH. Immunomodulatory substances of fungal origin. EOS-J. J Immunol Immunopharmacol 11: 115-122, 1991.
48. Stich HF, Rosin M. Naturally occurring phenols as antimutagenic and anticarcinogenic agents. Adv Exp Med Biol 177: 1-29, 1984.